Opinion

Definitive Healthcare Reports Financial Results for Fourth Quarter and Full Fiscal Year 2023

Retrieved on: 
星期三, 二月 28, 2024

FRAMINGHAM, Mass., Feb. 28, 2024 (GLOBE NEWSWIRE) -- Definitive Healthcare Corp. (“Definitive Healthcare” or the “Company”) (Nasdaq: DH), an industry leader in healthcare commercial intelligence, today announced financial results for the quarter and full year ended December 31, 2023. 

Key Points: 
  • FRAMINGHAM, Mass., Feb. 28, 2024 (GLOBE NEWSWIRE) -- Definitive Healthcare Corp. (“Definitive Healthcare” or the “Company”) (Nasdaq: DH), an industry leader in healthcare commercial intelligence, today announced financial results for the quarter and full year ended December 31, 2023.
  • Fourth Quarter 2023 Financial Highlights:
    Revenue was $65.9 million, an increase of 9% from $60.6 million in Q4 2022.
  • Full Year 2023 Financial Highlights:
    Revenue was $251.4 million for the year, an increase of 13% from $222.7 million for the full year 2022.
  • Definitive Healthcare will host a conference call on February 28, 2024, at 5:00 p.m. (Eastern Time) to discuss the Company's full financial results and current business outlook.

Monoamine Oxidase Type-B (MAO-B) Inhibitors for 7 MM: Market Size, Target Population, Competitive Landscape & Forecasts, 2034 - ResearchAndMarkets.com

Retrieved on: 
星期三, 三月 6, 2024

The "Monoamine Oxidase Type-B (MAO-B) Inhibitors Market Size, Target Population, Competitive Landscape & Market Forecast - 2034" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Monoamine Oxidase Type-B (MAO-B) Inhibitors Market Size, Target Population, Competitive Landscape & Market Forecast - 2034" report has been added to ResearchAndMarkets.com's offering.
  • The Monoamine Oxidase Type-B (MAO-B) Inhibitors market report provides insights around existing treatment practices in patients with Monoamine Oxidase Type-B (MAO-B) Inhibitors, approved (if any) and emerging Monoamine Oxidase Type-B (MAO-B) Inhibitors, market share of individual therapies, patient pool eligible for treatment with Monoamine Oxidase Type-B (MAO-B) Inhibitors, along with current and forecasted 7MM Monoamine Oxidase Type-B (MAO-B) Inhibitors market size from 2020-2034 by therapies and by indication.
  • This section will include details on changing Monoamine Oxidase Type-B (MAO-B) Inhibitors market dynamics post initiation of clinical development activities of the inhibitor.
  • The report covers information on collaborations, acquisitions and mergers, licensing, and patent details for Monoamine Oxidase Type-B (MAO-B) Inhibitors.

Ocean Capital Calls on Shareholders to Demand Accountability at UBS-Managed Puerto Rico Closed-End Funds

Retrieved on: 
星期二, 三月 5, 2024

In addition to electing Ocean Capital’s nominees, Ocean Capital has submitted a business proposal to terminate the investment advisory agreements with UBS at both of these upcoming annual meetings.

Key Points: 
  • In addition to electing Ocean Capital’s nominees, Ocean Capital has submitted a business proposal to terminate the investment advisory agreements with UBS at both of these upcoming annual meetings.
  • Ocean Capital will continue to do everything in its power to compel UBS and its affiliates to respect the will of shareholders.
  • VISIT WWW.IMPROVEUBSPRFUNDS.COM TO LEARN MORE ABOUT OCEAN CAPITAL’S CAMPAIGNS FOR VALUE-ENHANCING CHANGE AT THE FUNDS.
  • 2 The nine Funds include: Tax-Free Fixed Income Fund for Puerto Rico Residents, Inc. (“Fund I”), Tax-Free Fixed Income Fund II for Puerto Rico Residents, Inc. (“Fund II”), Tax-Free Fixed Income Fund III for Puerto Rico Residents, Inc. (“Fund III”), Tax-Free Fixed Income Fund IV for Puerto Rico Residents, Inc. (“Fund IV”), Tax-Free Fixed Income Fund V for Puerto Rico Residents, Inc. (“Fund V”), Puerto Rico Residents Tax-Free Fund, Inc. (“PRITF I”), Puerto Rico Residents Tax-Free Fund IV, Inc (“PRITF IV”), Puerto Rico Residents Tax-Free Fund VI, Inc. (“PRITF VI”) and Tax-Free Fund for Puerto Rico Residents (“TFF I”).

Aromatase Inhibitors (AIs) Market Size, Target Population, Competitive Landscape & Market Forecasts, 2020-2023 and 2024-2034 with Focus on 7 Major Markets - ResearchAndMarkets.com

Retrieved on: 
星期三, 二月 28, 2024

The "Aromatase Inhibitors (AIs) Market Size, Target Population, Competitive Landscape & Market Forecast - 2034" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Aromatase Inhibitors (AIs) Market Size, Target Population, Competitive Landscape & Market Forecast - 2034" report has been added to ResearchAndMarkets.com's offering.
  • The Aromatase Inhibitors (AIs) market report provides insights around existing treatment practices in patients with Aromatase Inhibitors (AIs), approved (if any) and emerging Aromatase Inhibitors (AIs), market share of individual therapies, patient pool eligible for treatment with Aromatase Inhibitors (AIs), along with current and forecasted 7MM Aromatase Inhibitors (AIs) market size from 2020-2034 by therapies and by indication.
  • Moreover, this segment will also give a brief overview around the existing treatment paradigm of the target indications.
  • This section will include details on changing Aromatase Inhibitors (AIs) market dynamics post initiation of clinical development activities of the inhibitor.

FcRn Inhibitor Market Size, Target Population, Competitive Landscape & Market Forecasts, 2020-2023 and 2024-2034 - ResearchAndMarkets.com

Retrieved on: 
星期五, 二月 23, 2024

The "FcRn Inhibitor Market Size, Target Population, Competitive Landscape & Market Forecast - 2034" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "FcRn Inhibitor Market Size, Target Population, Competitive Landscape & Market Forecast - 2034" report has been added to ResearchAndMarkets.com's offering.
  • This report delivers an in-depth understanding of FcRn Inhibitor, addressable patient pool, competitive landscape, and future market trends in the United States, EU4 (Germany, France, Italy, and Spain) and the UK, and Japan.
  • The FcRn Inhibitor market report provides insights around existing treatment practices in patients with FcRn Inhibitor, approved (if any) and emerging FcRn Inhibitor, market share of individual therapies, patient pool eligible for treatment with FcRn Inhibitor, along with current and forecasted 7MM FcRn Inhibitor market size from 2020-2034 by therapies and by indication.
  • This section will include details on changing FcRn Inhibitor market dynamics post initiation of clinical development activities of the inhibitor.

CDK4/6 Inhibitor Market Size, Target Population, Competitive Landscape & Market Forecasts 2023-2034 - ResearchAndMarkets.com

Retrieved on: 
星期五, 二月 23, 2024

The "CDK4/6 Inhibitor Market Size, Target Population, Competitive Landscape & Market Forecast - 2034" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "CDK4/6 Inhibitor Market Size, Target Population, Competitive Landscape & Market Forecast - 2034" report has been added to ResearchAndMarkets.com's offering.
  • This report delivers an in-depth understanding of CDK4/6 Inhibitor, addressable patient pool, competitive landscape, and future market trends in the United States, EU4 (Germany, France, Italy, and Spain) and the UK, and Japan.
  • The CDK4/6 Inhibitor market report provides insights around existing treatment practices in patients with CDK4/6 Inhibitor, approved (if any) and emerging CDK4/6 Inhibitor, market share of individual therapies, patient pool eligible for treatment with CDK4/6 Inhibitor, along with current and forecasted 7MM CDK4/6 Inhibitor market size from 2020-2034 by therapies and by indication.
  • This section will include details on changing CDK4/6 Inhibitor market dynamics post initiation of clinical development activities of the inhibitor.

Janus Kinase (JAK) Inhibitor Market Size, Target Population, Competitive Landscape & Market Forecasts, 2034 - ResearchAndMarkets.com

Retrieved on: 
星期四, 二月 22, 2024

The "Janus Kinase (JAK) Inhibitor Market Size, Target Population, Competitive Landscape & Market Forecast - 2034" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Janus Kinase (JAK) Inhibitor Market Size, Target Population, Competitive Landscape & Market Forecast - 2034" report has been added to ResearchAndMarkets.com's offering.
  • The Janus Kinase (JAK) Inhibitor market report provides insights around existing treatment practices in patients with Janus Kinase (JAK) Inhibitor, approved (if any) and emerging Janus Kinase (JAK) Inhibitor, market share of individual therapies, patient pool eligible for treatment with Janus Kinase (JAK) Inhibitor, along with current and forecasted 7MM Janus Kinase (JAK) Inhibitor market size from 2020-2034 by therapies and by indication.
  • Apart from a comprehensive Janus Kinase (JAK) Inhibitor competitive landscape in tabular form, the emerging KRAS Inhibitor chapters provides the product details and other development activities of the emerging Janus Kinase (JAK) Inhibitor under the late and mid-stage of clinical development for various indications.
  • This section will include details on changing Janus Kinase (JAK) Inhibitor market dynamics post initiation of clinical development activities of the inhibitor.

New Study Shows Healthcare Professionals' Current Student Loan Debt is at Least Half of Their Salary

Retrieved on: 
星期一, 二月 26, 2024

NEW YORK, Feb. 26, 2024 /PRNewswire/ -- As conversations around federal student loan forgiveness continue and repayment has resumed for most, borrowers have begun to feel the steady impact on their finances. A new survey released today by Laurel Road, a digital banking platform of KeyBank with specialized offerings for healthcare and business professionals, analyzes the unique financial reality faced by healthcare professionals.

Key Points: 
  • The survey found that for both nurses and doctors, their current student debt equals more than half of their current annual salary, highlighting a significant debt-to-income ratio in the healthcare industry.
  • Nurses reported an average income before taxes of $80,695 with an average student loan debt of $40,611, while doctors have an average income before taxes of $323,693 with an average student loan debt of $188,317.
  • Notably, Gen Z doctors at the beginning of their careers earn an average of $183,873 annually while facing $117,206 in student loan debt – nearly 64% of their salary.
  • Despite feeling stress caused by their student loan debt, not all healthcare professionals are eager to seek help from a financial professional.

The Podcast Academy Announces Nominees for Fourth Annual Awards For Excellence In Audio

Retrieved on: 
星期五, 二月 16, 2024

LOS ANGELES, Feb. 16, 2024 /PRNewswire-PRWeb/ -- The Podcast Academy (TPA), the preeminent professional podcast organization, has announced the nominees for its fourth annual Awards for Excellence in Audio (The Ambies). The Ambies will take place on Tuesday, March 26 at the JW Marriott LA Live Los Angeles.

Key Points: 
  • Best Original Score and Music Supervision:
    Louder Than A Riot – Suzi Analogue, Kassa Overall, and Ramtin Arablouei
    Best Performance in Audio Fiction:
    Scrooge: A Christmas Carol – Sean Astin, John Rhys-Davies, Lucy Punch, Ben Barnes, Juliet Mills, Ryan O'Quinn, Bethany Joy Lenz, Clive Standen, Maxwell Caulfield
    Supreme: The Battle for Roe – Maya Hawke, William H. Macy, Abigail Breslin, et al.
  • The Salvation – Rose Leslie, Toby Jones, Robert Bathurst, et al.
  • The Very Worst Thing that Could Possibly Happen – Antonia Desplat, Isaac Gonzalez Rossi Yvette Lu, et al.
  • Yes We Cannabis – Sam Richardson, Method Man, Langston Kerman, Punkie Johnson, Richard Kind, Laci Mosley, Anjelah Johnson-Reyes, Heidi Gardner, Tichina Arnold, Tim Meadows, Rachel Dratch, Chris Parnell
    Best Personal Growth / Spirituality Podcast:
    Best Podcast Host or Hosts:
    David Rind – Tug of War: Israel-Hamas War
    Isaac-Davy Aronson & Rachel Maddow – Rachel Maddow Presents: Déjà News
    Martine Powers – Post Reports: The Empty Grave of Comrade Bishop
    Rose Reid & Nando Vila – Shoot the Messenger: Espionage, Murder & Pegasus Spyware
    Best Politics or Opinion Podcast:

Just Published: 'MAGA Republicans Are Already Normal -- And Other Shocking Notions'

Retrieved on: 
星期二, 二月 13, 2024

CINCINNATI, Feb. 13, 2024 /PRNewswire-PRWeb/ -- Former Washington Post contributing columnist Gary Abernathy's new book, "MAGA Republicans Are Already Normal – And Other Shocking Notions," is now available in hardcover, paperback and eBook on Amazon.

Key Points: 
  • CINCINNATI, Feb. 13, 2024 /PRNewswire-PRWeb/ -- Former Washington Post contributing columnist Gary Abernathy's new book, "MAGA Republicans Are Already Normal – And Other Shocking Notions," is now available in hardcover, paperback and eBook on Amazon.
  • He predicted early in the process that the billionaire businessman and reality TV star would win the GOP presidential nomination.
  • Throughout the campaign and in the months following Trump's historic upset victory, Abernathy continued writing about Trump.
  • "MAGA Republicans Are Already Normal" opens with a collection of the columns written for the Times-Gazette that caught the attention of the Post.